Shandong Qilu King-Phar Pharmaceutical

Shandong Qilu King-Phar Pharmaceutical is an operating subsidiary of Qilu Pharmaceutical Group focused on commercial manufacturing of fermentation-derived antibiotic active pharmaceutical ingredients and veterinary premixes. The site is described by the company as Qilu's fermentation processing plant and one of the group's manufacturing sites specializing in antibiotic APIs and premixes. Its marketed products visible on the company's website include apramycin sulfate, apramycin sulfate soluble powder, monensin premix, salinomycin premix, maduramicin ammonium, compound maduramicin ammonium premix, ivermectin, avermectin, kanamycin monosulfate, kanamycin B, spectinomycin hydrochloride/sulfate, and diclazuril premix. The company appears to be a manufacturing- and export-oriented business rather than a discovery-stage biotech, with Chinese GMP compliance and some products approved by regulators including the US FDA, EDQM, and APVMA. It primarily serves animal-health and anti-infective markets through large-scale fermentation and premix production.